Progress in synthetic biology of pinocembrin.
- Author:
Lei GUO
;
Jianqiang KONG
- Publication Type:Journal Article
- MeSH:
Biosynthetic Pathways;
Fermentation;
Flavanones;
biosynthesis;
Industrial Microbiology;
Plants;
Synthetic Biology
- From:
Chinese Journal of Biotechnology
2015;31(4):451-460
- CountryChina
- Language:Chinese
-
Abstract:
Pinocembrin, belonging to flavanons, was isolated from various plants. Pinocembrin has a variety of pharmacological activities, such as neuroprotective effect, antimicrobial activity, and antioxidant efficacy. Pinocembrin was approved as class I drugs to its phase II clinical trial by CFDA in 2009, mainly used for the treatment of ischemic stroke. As a promising compound, the manufacturing technologies of pinocembrin, including chemical synthesis, extraction from plant and synthetic biology, have attracted many attentions. Compared with the first two technologies, synthetic biology has many advantages, such as environment-friendly and low-cost. Construction of biosynthetic pathway in microorganism offers promising results for large scale pinocembrin production by fermentation after taking lots of effective strategies. This article reviews some of recent strategies in microorganisms to improve the yield, with focus on the selection of appropriate the key enzyme sources, the supply of precursors and cofactors by microorganisms, the choice of substance and the level of the key enzyme expression.
